Sign In
Buy CPIX
$5.83
+0.260 (+4.67%)
At Close: Jun 23, 2026
RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement
04:10pm, Monday, 22'nd Jun 2026
$6 million upfront with up to approximately $13.4 million of potential aggregate gross proceeds upon the exercise in full of warrants TEL AVIV, Israel and RALEIGH, N.C., June 22, 2026 /PRNewswire/ --
RedHill Biopharma Announces Up To $19.4 Million Private Placement
08:00am, Thursday, 18'th Jun 2026
$6 million upfront with up to approximately $13.4 million of potential aggregate gross proceeds upon the exercise in full of warrants TEL AVIV, Israel & RALEIGH, N.C., June 18, 2026 /PRNewswire/ -- R
RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation
07:00am, Tuesday, 09'th Jun 2026
The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of cancer most commonly affecting babies and young
RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo
07:00am, Monday, 08'th Jun 2026
RALEIGH, N.C. and TEL-AVIV, Israel, June 8, 2026 /PRNewswire/ -- RedHill Biopharma Ltd.
Cumberland's Ifetroban Shows Potential to Limit Metastasis
10:06am, Thursday, 04'th Jun 2026
CPIX reports positive Phase 2a results for Ifetroban, showing a favorable safety profile and promising early signs of reducing cancer metastasis in high-risk patients.
Cumberland Expands Global Reach With Vibativ Launch in China
10:11am, Tuesday, 02'nd Jun 2026
CPIX launches Vibativ in China through SciClone, expanding access to its antibiotic treatment for serious Gram-positive bacterial infections.
Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis
09:05am, Tuesday, 02'nd Jun 2026
Positive Results from Phase 2a Clinical Trial Study met its primary endpoint demonstrating safety and tolerability of ifetroban in patients with high-risk solid tumors Trial revealed promising effica
Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or vaccines, RedHill Biopharma is actively d
CUMBERLAND PHARMACEUTICALS ANNOUNCES LAUNCH OF VIBATIV® IN CHINA
09:05am, Thursday, 28'th May 2026
Commercialization in China through partnership with SciClone Pharmaceuticals Expands access to potentially life-saving antibiotic in the world's second-largest pharmaceutical market NASHVILLE, Tenn.
Cumberland Posts Loss in Q1 Amid $100M Apotex Deal Plan
11:15am, Wednesday, 06'th May 2026
CPIX posts a wider y//y loss in Q1, as it unveils a $100-million Apotex deal and sharpens focus on orphan drug development.
Cumberland Pharmaceuticals Inc. (CPIX) Q1 2026 Earnings Call Transcript
02:31am, Wednesday, 06'th May 2026
Cumberland Pharmaceuticals Inc. (CPIX) Q1 2026 Earnings Call Transcript
CUMBERLAND PHARMACEUTICALS REPORTS Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE
05:00pm, Tuesday, 05'th May 2026
Enters into Strategic Transaction, unlocking $100 million in value Sharpens focus on Orphan Drug candidates to address unmet medical needs NASHVILLE, Tenn., May 5, 2026 /PRNewswire/ -- Cumberland Phar
RHB-2041 is a next-generation optimized formulation of RedHill's oral RHB-104 2 , designed for enhanced tolerability, safety profile and patient adherence, that employs a groundbreaking Mycobacterium
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE
04:05pm, Tuesday, 28'th Apr 2026
NASHVILLE, Tenn., April 28, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2026 financi
RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights
08:00am, Monday, 27'th Apr 2026
2025 was a year of tenacity, strategic transactions and building traction for RedHill Talicia® business transformed: Formation of Talicia Holdings Inc. (THI) and the U.S. co-commercialization partne
